MCID: CYT018
MIFTS: 27

Cytochrome P450 2d6 Variant

Categories: Rare diseases

Aliases & Classifications for Cytochrome P450 2d6 Variant

MalaCards integrated aliases for Cytochrome P450 2d6 Variant:

Name: Cytochrome P450 2d6 Variant 52
Human Cytochrome P450 2d6 52
Cytochrome P450 52
Cyp2d6 52

Classifications:



Summaries for Cytochrome P450 2d6 Variant

MalaCards based summary : Cytochrome P450 2d6 Variant, also known as human cytochrome p450 2d6, is related to disordered steroidogenesis due to cytochrome p450 oxidoreductase deficiency and cytochrome p450 oxidoreductase deficiency. The drugs Naproxen and Diclofenac have been mentioned in the context of this disorder. Affiliated tissues include breast, liver and lung.

Wikipedia : 74 Cytochrome P450 2D6 (CYP2D6) is an enzyme that in humans is encoded by the CYP2D6 gene. CYP2D6 is... more...

Related Diseases for Cytochrome P450 2d6 Variant

Diseases related to Cytochrome P450 2d6 Variant via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 812)
# Related Disease Score Top Affiliating Genes
1 disordered steroidogenesis due to cytochrome p450 oxidoreductase deficiency 13.1
2 cytochrome p450 oxidoreductase deficiency 13.0
3 aromatase deficiency 11.9
4 antley-bixler syndrome 11.8
5 antley-bixler syndrome with genital anomalies and disordered steroidogenesis 11.8
6 breast cancer 11.7
7 lung cancer 11.7
8 anxiety 11.6
9 schizophrenia 11.6
10 parkinson disease, late-onset 11.6
11 autoimmune hepatitis 11.6
12 major depressive disorder 11.6
13 alzheimer disease 11.5
14 attention deficit-hyperactivity disorder 11.5
15 neuroleptic malignant syndrome 11.5
16 hypertension, essential 11.5
17 basal cell carcinoma 11.5
18 movement disease 11.5
19 plasmodium vivax malaria 11.5
20 corticosterone methyloxidase type i deficiency 11.5
21 obsessive-compulsive disorder 11.5
22 psychotic disorder 11.5
23 dystonia 11.5
24 diarrhea 11.4
25 diabetes mellitus, noninsulin-dependent 11.4
26 dementia, lewy body 11.4
27 substance abuse 11.4
28 systolic heart failure 11.4
29 migraine with or without aura 1 11.4
30 pulmonary disease, chronic obstructive 11.4
31 human immunodeficiency virus type 1 11.4
32 drug-induced hepatitis 11.4
33 multiple chemical sensitivity 11.4
34 substance dependence 11.4
35 tardive dyskinesia 11.4
36 mental depression 11.4
37 pain agnosia 11.3
38 sexual disorder 11.3
39 serotonin syndrome 11.3
40 progesterone-receptor positive breast cancer 11.3
41 galactorrhea 11.3
42 polycystic kidney disease 11.2
43 malaria 11.2
44 gastroparesis 11.2
45 neuroblastoma 11.2
46 generalized anxiety disorder 11.1
47 hepatitis d 11.1
48 motor neuron disease 11.1
49 codeine toxicity 11.1
50 alcoholic hepatitis 11.1

Graphical network of the top 20 diseases related to Cytochrome P450 2d6 Variant:



Diseases related to Cytochrome P450 2d6 Variant

Symptoms & Phenotypes for Cytochrome P450 2d6 Variant

Drugs & Therapeutics for Cytochrome P450 2d6 Variant

Drugs for Cytochrome P450 2d6 Variant (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 729)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Naproxen Approved, Vet_approved Phase 4 22204-53-1 1302 156391
2
Diclofenac Approved, Vet_approved Phase 4 15307-86-5 3033
3
Lactulose Approved Phase 4 4618-18-2 11333
4
Perphenazine Approved Phase 4 58-39-9 4748
5
Amitriptyline Approved Phase 4 50-48-6 2160
6
Caffeine Approved Phase 4 58-08-2 2519
7
Bupropion Approved Phase 4 34911-55-2, 34841-39-9 444
8
Tramadol Approved, Investigational Phase 4 27203-92-5 33741
9
Tolbutamide Approved, Investigational Phase 4 64-77-7 5505
10
Digoxin Approved Phase 4 20830-75-5 30322 2724385
11
Norepinephrine Approved Phase 4 51-41-2 439260
12
Metronidazole Approved Phase 4 443-48-1 4173
13
Quinidine Approved, Investigational Phase 4 56-54-2 441074
14
Itraconazole Approved, Investigational Phase 4 84625-61-6 55283
15
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
16
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
17
Chlorzoxazone Approved Phase 4 95-25-0 2733
18
Nicotine Approved Phase 4 54-11-5 942 89594
19
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613
20
Rabeprazole Approved, Investigational Phase 4 117976-89-3 5029
21
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
22
Triflusal Approved, Investigational Phase 4 322-79-2
23
Sirolimus Approved, Investigational Phase 4 53123-88-9 5284616 6436030 46835353
24
Everolimus Approved Phase 4 159351-69-6 6442177 70789204
25
Oxcarbazepine Approved Phase 4 28721-07-5 34312
26
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
27
Acenocoumarol Approved, Investigational Phase 4 152-72-7 9052 54676537
28
Nevirapine Approved Phase 4 129618-40-2 4463
29
Erythromycin Approved, Investigational, Vet_approved Phase 4 114-07-8 12560 441411
30
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
31
Efavirenz Approved, Investigational Phase 4 154598-52-4 64139
32
Piroxicam Approved, Investigational Phase 4 36322-90-4 5280452 54676228
33
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
34
Citalopram Approved Phase 4 59729-33-8 2771
35
Lopinavir Approved Phase 4 192725-17-0 92727
36
Tenoxicam Approved Phase 4 59804-37-4 5312154
37
Ziprasidone Approved Phase 4 146939-27-7 60854
38
Diltiazem Approved, Investigational Phase 4 42399-41-7 39186
39
Levofloxacin Approved, Investigational Phase 4 100986-85-4 149096
40
Ofloxacin Approved Phase 4 82419-36-1 4583
41
Eptifibatide Approved, Investigational Phase 4 188627-80-7 123610
42
Mefloquine Approved, Investigational Phase 4 53230-10-7 4046
43
Sunitinib Approved, Investigational Phase 4 341031-54-7, 557795-19-4 5329102
44
Amlodipine Approved Phase 4 88150-42-9 2162
45
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
46
Prednisolone Approved, Vet_approved Phase 4 50-24-8 5755
47
Methylprednisolone hemisuccinate Approved Phase 4 2921-57-5
48
Methylprednisolone Approved, Vet_approved Phase 4 83-43-2 6741
49 Prednisolone acetate Approved, Vet_approved Phase 4 52-21-1
50
Prednisolone phosphate Approved, Vet_approved Phase 4 302-25-0

Interventional clinical trials:

(show top 50) (show all 747)
# Name Status NCT ID Phase Drugs
1 The Dynamic Effect of Non-cytochrome P450 Isoenzyme 3A4(CYP3A4)-Metabolized and Cytochrome P450 Isoenzyme 3A4(CYP3A4)-Metabolized Statins on Clopidogrel Resistance in Patients With Cerebral Infarction Unknown status NCT02411903 Phase 4 atorvastatin and clopidogrel;rosuvastatin and clopidogrel
2 Tailored Therapy Versus Standard Triple Therapy for Helicobacter Pylori Eradication in Children: A Randomized Trial Unknown status NCT02635191 Phase 4 Tailored Group;Standard group
3 Influence of Recipient Cytochrome P450 3A5 Polymorphism on the Metabolism of Prolonged Release Tacrolimus Administered de Novo After Renal Transplantation Unknown status NCT02311010 Phase 4 Advagraf
4 Clinical Pharmacokinetics of Cytochrome P450: Influence on the Pharmacokinetics of Naproxen (CYP2C8 and CYP2C9) and Associated Naproxen-esomeprazole (CYP2C19) Unknown status NCT03092193 Phase 4 Naproxen;Naproxen-esomeprazole
5 Pharmacodynamic Comparison of Pitavastatin Versus Atorvastatin on Platelet Reactivity in Patients With Coronary Artery Disease Treated With Dual Antiplatelet Therapy - The PORTO Trial Unknown status NCT01648829 Phase 4 Atorvastatin;Pitavastatin
6 Pharmacodynamic Effects of Atorvastatin vs. Rosuvastatin on pLatelet Reactivity in Stable Patients With Coronary Artery Disease Treated With Dual Antiplatelet Therapy Unknown status NCT01567774 Phase 4 Atorvastatin;Rosuvastatin
7 Efficacy of 10-day Concomitant Regimen Versus High Dose Dual Therapy in Anti-Helicobacter Pylori Rescue Therapy Unknown status NCT01265069 Phase 4 high dose dual therapy;concomitant therapy
8 Adjusting Antiretroviral Therapy Dosage Using Therapeutic Drug Monitoring Unknown status NCT00836212 Phase 4 Reducing dose of Lopinavir;Reducing dose of efavirenz
9 In Vivo Inhibition Profile of CYP2C9 by Pineapple Juice Unknown status NCT01649492 Phase 4
10 The Pharmacokinetics of Fentanyl in Intensive Care Patients Unknown status NCT02587273 Phase 4 Fentanyl
11 An Open-label, Randomised Pilot Study Comparing the Efficacy, Safety and Tolerability of Raltegravir With Protease Inhibitor-based Therapy in Treatment-naïve, HIV/Hepatitis C Co-infected Injecting Drug Users Receiving Methadone Unknown status NCT01105611 Phase 4 Raltegravir;Atazanavir/Ritonavir
12 Pharmacokinetic Interaction Between Coartem® and Either Nevirapine, Efavirenz or Rifampicin in HIV Positive Ugandan Patients Unknown status NCT00620438 Phase 4 Lumefantrine-artemether and nevirapine;lumefantrine-artemether and efavirenz;Lumefantrine-artemether and rifampicin
13 Paroxetines Effect on Tramadols Metabolism and Pharmakodynamics: a Dose Response Study Unknown status NCT00785603 Phase 4 Paroxetine;Paroxetin placebo;Tramadol
14 Fixed-dose vs. Phenotype-based PrAsugrel Dose to MATCH Therapeutic Zone in Asians With Acute Coronary Syndrome Unknown status NCT01951001 Phase 4 Prasugrel
15 Comparison of the Efficacy of Triple Therapy With or Without Acetylcysteine in the First Line of Helicobacter Pylori Infection- A Multicenter Randomized Comparative Trial Unknown status NCT02249546 Phase 4 N-acetylcysteine + PPI-amoxicillin-clarithromycin;PPI-amoxicillin-clarithromycin
16 Phase 4 Study of Clinical Pharmacogenomics of Antidepressant Response Unknown status NCT00269334 Phase 4 Using Citalopram(drug) or Paroxetine(drug)
17 Open Labeled, Propective, Multicentric Phase IV Study to Examine the Influence of Pharmacogenetic Markers on the Efficacy and Side Effects in Postmenopausal, Steroid Hormone Positive Breast Cancer Patients, Who Are Treated With Letrozol. Unknown status NCT01908556 Phase 4 Letrozole
18 Clinical Trial Simulation Using ODE/PDE Hemodialysis Model for Quantifying Oxycodone's Removal in End-Stage Kidney Disease Unknown status NCT02452437 Phase 4 Oxycodone
19 Effects and Cost-Effectiveness of Pharmacogenetic Screening Among Elderly Starters With Antidepressants: A Pragmatic Randomized Controlled Trial Completed NCT01778907 Phase 4
20 Influence of Uncontrolled Diabetes on the Kinetic Disposition, Metabolism and Pharmacokinetics-pharmacodynamics of Tramadol Enantiomers in Patients With Neuropathic Pain Completed NCT02246712 Phase 4 Single oral dose of 100 mg racemic tramadol
21 Pharmacokinetics of Intravenous Acetaminophen and Its Metabolites in Morbidly Obese Patients Completed NCT01764555 Phase 4 acetaminophen 2 g
22 Genetic-determinants of Protease Inhibitor Pharmacology Completed NCT01388543 Phase 4 Atazanavir
23 Comparison of Triflusal and Clopidogrel Effect in Secondary Prevention of Stroke Based on the Cytochrome P450 2C19 Genotyping Completed NCT01174693 Phase 4 Triflusal;Clopidogrel
24 Evaluation of the Effect of Kava on Drug Metabolism Enzymes and EEG Measured Beta Amplitude Completed NCT00009542 Phase 4 kava (Piper methysticum)
25 Induction of Drug Metabolism: A Comparative, Pharmacokinetic in Vivo Study of the Effect of Carbamazepine and Oxcarbazepine on CYP3A4. Completed NCT00260247 Phase 4 carbamazepine oxcarbazepine
26 Evaluation of the Strategies of Switching Schizophrenia Patients to Aripiprazole From Other Antipsychotic Agents: Combination of Pharmacogenomics and Therapeutic Drug Monitoring Completed NCT00545467 Phase 4 Aripiprazole
27 Evaluation of the Effect of the H2 Haplotype and CYP3As Polymorphisms on the Antiplatelet Response to Clopidogrel Given Before Elective Percutaneous Coronary Intervention Completed NCT00433784 Phase 4 Clopidogrel
28 Influence of Cytochrome P450 (CYP2C9) Genotype on Clinical Efficacy of Tenoxicam After Lower Third Molars Surgeries Completed NCT04182191 Phase 4 Tenoxicam
29 Randomized Controlled Trial of The Safety and Efficacy of Aripiprazole VS Ziprasidone in Schizophrenic Patients With Metabolic Syndrome and Diabetes Mellitus. Completed NCT01714011 Phase 4 Ziprasidone;Aripiprazole
30 The Effect of Concomitant Administration of Erythromycin and Diltiazem on CYP3A Activity in Healthy Volunteers Completed NCT00318201 Phase 4 Erythromycin;Diltiazem
31 Effects of Different Omeprazole Dosing on Gastric pH in Non- Variceal Upper Gastrointestinal Bleeding: A Randomized Prospective Study Completed NCT03980496 Phase 4 Omeprazole
32 Pharmacodynamic Comparison of Prasugrel Versus Ticagrelor in Patients With CYP2C19 Loss-of-function Genotype: a Validation Study in Patients With Stable Coronary Artery Disease Completed NCT03489863 Phase 4 Prasugrel;Ticagrelor
33 A Pharmacodynamic Study Comparing Prasugrel Versus Ticagrelor in Patients With Coronary Artery Disease Undergoing PCI With CYP2C19 Loss-of-function Genotypes: A Feasibility Study With Point-of-care Pharmacodynamic and Genetic Testing Completed NCT02065479 Phase 4 Prasugrel;Ticagrelor
34 Genotype Guided Versus Conventional Approach in Selection of Oral P2Y12 Receptor Blocker in Chinese Patients Suffering From Acute Coronary Syndrome Completed NCT01994941 Phase 4 Clopidogrel;Ticagrelor
35 Open-Label Study to Evaluate Potential Pharmacokinetic and Pharmacodynamic Interactions of Orally Administered Mefloquine and Dihydroartemisinin-Piperaquine in Healthy Adult Subjects Completed NCT02324738 Phase 4 Mefloquine and Dihydroartemisinin-piperaquine;Mefloquine
36 Physiological Study of the Human CYP3A Activity (PiSA) Completed NCT03204578 Phase 4 AB (Midazolam OD formulation/Dormicum);BA (Dormicum/Midazolam OD formulation)
37 Pupillary Changes as a Potential Biomarker for Escitalopram in Relation to CYP2C19 Polymorphism Completed NCT00397059 Phase 4 Escitalopram
38 Effect of Amlodipine on Platelet Inhibition by Clopidogrel in Patients With Ischemic Heart Disease- a Prospective Randomized Controlled Trial Completed NCT01203696 Phase 4 Amlodipine;Amlodipine
39 Global Initiative to Characterize Differences in Antiretroviral Pharmacokinetics in HIV-Infected Populations Completed NCT00054743 Phase 4
40 Prospective Study:Clinical Trial on the Tacrolimus Dosage Range in Chinese Renal Transplant Recipients With Different Genetic Phenotypes of Drug Metabolizing Enzymes(CYP3A5) Completed NCT00935298 Phase 4 Tacrolimus
41 Comparison of Nevirapine Levels With and Without Dose Escalation in HIV-infected Patients Commencing Antiretroviral Therapy Who Are Also Receiving Rifampicin Based Anti-tuberculous Therapy Completed NCT00617643 Phase 4 Nevirapine without dose escalation;Nevirapine initiation with dose escalation
42 Modulation of Opioid Effects by Garlic Supplements Completed NCT00499460 Phase 4 oxycodone
43 Interventional Multicentre Pharmacokinetic Study of Adoport® (Tacrolimus) in Patients With de Novo Kidney Transplantation Completed NCT03076151 Phase 4 Tacrolimus monohydrate (ADOPORT®)
44 The Effect of Everolimus on the Pharmacokinetics of Tacrolimus in Renal Transplant Patients, and the Effect of ABCB1、CYP3A4、CYP3A5、PORGenetic Polymorphism on the Two Drugs Completed NCT02077556 Phase 4 Everolimus;Mycophenolate mofetil;Tacrolimus;Methylprednisolone;Prednisolone
45 EUropean Pharmacogenetics of AntiCoagulant Therapy - Warfarin Completed NCT01119300 Phase 4
46 EUropean Pharmacogenetics of AntiCoagulant Therapy - Phenprocoumon Completed NCT01119274 Phase 4
47 EUropean Pharmacogenetics of AntiCoagulant Therapy - Acenocoumarol Completed NCT01119261 Phase 4
48 Influence of Genotype of Cytochrome P450 (CYP2C9) on Clinical Efficacy and Pharmacokinetics of Piroxicam After Lower Third Molar Surgery Completed NCT02450487 Phase 4 Piroxicam
49 A Randomized Crossover Study of the Effects of Zinc Sulphate Supplementation on Atazanavir/Ritonavir-associated Hyperbilirubinemia Completed NCT01475227 Phase 4 1 Solvazinc tablet, day 2 to day 15;1 Solvazinc tablet, day 15 to day 28
50 Herb-Opioid Interactions Completed NCT00027014 Phase 4 St. John's Wort;oxycodone;fentanyl

Search NIH Clinical Center for Cytochrome P450 2d6 Variant

Genetic Tests for Cytochrome P450 2d6 Variant

Anatomical Context for Cytochrome P450 2d6 Variant

MalaCards organs/tissues related to Cytochrome P450 2d6 Variant:

40
Breast, Liver, Lung, Testes, Kidney, Prostate, Heart

Publications for Cytochrome P450 2d6 Variant

Articles related to Cytochrome P450 2d6 Variant:

(show top 50) (show all 67)
# Title Authors PMID Year
1
Plasma proteomic analysis of autoimmune hepatitis in an improved AIH mouse model. 61
31906950 2020
2
Mitochondrially targeted cytochrome P450 2D6 is involved in monomethylamine-induced neuronal damage in mouse models. 61
31113867 2019
3
Cytochrome P450 2D6 profiles and their relationship with outcomes of primaquine anti-relapse therapy in Australian Defence Force personnel deployed to Papua New Guinea and East Timor. 61
30999967 2019
4
Conversion of Cytochrome P450 2D6 of Human Into a FRET-Based Tool for Real-Time Monitoring of Ajmalicine in Living Cells. 61
31828069 2019
5
Kinetic mechanism of time-dependent inhibition of CYP2D6 by 3,4-methylenedioxymethamphetamine (MDMA): Functional heterogeneity of the enzyme and the reversibility of its inactivation. 61
30114388 2018
6
Understanding human genetic factors influencing primaquine safety and efficacy to guide primaquine roll-out in a pre-elimination setting in southern Africa. 61
29558929 2018
7
A combinatorial approach for the discovery of cytochrome P450 2D6 inhibitors from nature. 61
28808272 2017
8
Impact of CYP2D6 Polymorphisms on Postoperative Fentanyl Analgesia in Gastric Cancer Patients. 61
25825958 2015
9
Impact of physiological, pathological and environmental factors on the expression and activity of human cytochrome P450 2D6 and implications in precision medicine. 61
26574146 2015
10
Simulation with cells in vitro of tamoxifen treatment in premenopausal breast cancer patients with different CYP2D6 genotypes. 61
25073551 2014
11
Mechanism of autoimmune hepatic fibrogenesis induced by an adenovirus encoding the human liver autoantigen cytochrome P450 2D6. 61
23809878 2013
12
Double site saturation mutagenesis of the human cytochrome P450 2D6 results in regioselective steroid hydroxylation. 61
23552177 2013
13
Molecular mimicry rather than identity breaks T-cell tolerance in the CYP2D6 mouse model for human autoimmune hepatitis. 61
23200317 2013
14
Metabolism of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by mitochondrion-targeted cytochrome P450 2D6: implications in Parkinson disease. 61
23258538 2013
15
No association between cytochrome P450 2D6 gene polymorphism and risk of acute leukemia: evidence based on a meta-analysis. 61
24112176 2013
16
Production of human cytochrome P450 2D6 drug metabolites with recombinant microbes--a comparative study. 61
22930520 2012
17
Pharmacophore, QSAR, and binding mode studies of substrates of human cytochrome P450 2D6 (CYP2D6) using molecular docking and virtual mutations and an application to chinese herbal medicine screening. 61
22039821 2012
18
Binding of quinidine radically increases the stability and decreases the flexibility of the cytochrome P450 2D6 active site. 61
22459173 2012
19
Molecular analysis and modeling of inactivation of human CYP2D6 by four mechanism based inactivators. 61
22372551 2012
20
Crystal structure of human cytochrome P450 2D6 with prinomastat bound. 61
22308038 2012
21
Modeling human cytochrome P450 2D6 metabolism and drug-drug interaction by a novel panel of knockout and humanized mouse lines. 61
21989258 2012
22
Ligand- and protein-based modeling studies of the inhibitors of human cytochrome P450 2D6 and a virtual screening for potential inhibitors from the Chinese herbal medicine, Scutellaria baicalensis (Huangqin,Baikal Skullcap). 61
21846324 2012
23
Substituted imidazole of 5-fluoro-2-[4-[(2-phenyl-1H-imidazol-5-yl)methyl]-1-piperazinyl]pyrimidine Inactivates cytochrome P450 2D6 by protein adduction. 61
21422192 2011
24
Comparison of cytochrome P450 2D6 and variants in terms of drug oxidation rates and substrate inhibition. 61
21453270 2011
25
Evolution of the CYP2D gene cluster in humans and four non-human primates. 61
21670550 2011
26
Identification of genetic variants of human cytochrome P450 2D6 with impaired mitochondrial targeting. 61
19781968 2010
27
Human liver mitochondrial cytochrome P450 2D6--individual variations and implications in drug metabolism. 61
19438707 2009
28
Mass spectrometry-based absolute quantification of microsomal cytochrome P450 2D6 in human liver. 61
19402041 2009
29
Biotechnological synthesis of the designer drug metabolite 4'-hydroxymethyl-alpha-pyrrolidinohexanophenone in fission yeast heterologously expressing human cytochrome P450 2D6--a versatile alternative to multistep chemical synthesis. 61
19470220 2009
30
New insights into the structural characteristics and functional relevance of the human cytochrome P450 2D6 enzyme. 61
19645588 2009
31
Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I. 61
19817501 2009
32
Substrate specificity, inhibitors and regulation of human cytochrome P450 2D6 and implications in drug development. 61
19601803 2009
33
Quantitation of human cytochrome P450 2D6 protein with immunoblot and mass spectrometry analysis. 61
18832475 2009
34
Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II. 61
19902987 2009
35
Comparative preclinical drug metabolism and pharmacokinetic evaluation of novel 4-aminoquinoline anti-malarials. 61
18563832 2009
36
In vitro metabolism studies of new adenosine A 2A receptor antagonists. 61
19356109 2008
37
Design and synthesis of 6-fluoro-2-naphthyl derivatives as novel CCR3 antagonists with reduced CYP2D6 inhibition. 61
18752960 2008
38
Association between CYP2D6 *10 genotype and survival of breast cancer patients receiving tamoxifen treatment. 61
18407954 2008
39
Genetic polymorphism of hepatocyte nuclear factor-4alpha influences human cytochrome P450 2D6 activity. 61
18666237 2008
40
Breaking tolerance to the natural human liver autoantigen cytochrome P450 2D6 by virus infection. 61
18474629 2008
41
Structural rationalization of novel drug metabolizing mutants of cytochrome P450 BM3. 61
17957765 2008
42
Development and validation of a chemical hydrolysis method for dextromethorphan and dextrophan determination in urine samples: application to the assessment of CYP2D6 activity in fibromyalgia patients. 61
18065299 2008
43
Biotechnological synthesis of drug metabolites using human cytochrome P450 2D6 heterologously expressed in fission yeast exemplified for the designer drug metabolite 4'-hydroxymethyl-alpha-pyrrolidinobutyrophenone. 61
17572388 2007
44
Allelic distributions of CYP2D6 gene copy number variation in the Eastern Han Chinese population. 61
17241532 2007
45
Classification of highly unbalanced CYP450 data of drugs using cost sensitive machine learning techniques. 61
17238253 2007
46
Comparative aromatic hydroxylation and N-demethylation of MPTP neurotoxin and its analogs, N-methylated beta-carboline and isoquinoline alkaloids, by human cytochrome P450 2D6. 61
16870220 2006
47
Crystal structure of human cytochrome P450 2D6. 61
16352597 2006
48
Three new alternative splicing variants of human cytochrome P450 2D6 mRNA in human extratumoral liver tissue. 61
15484318 2004
49
Identification of human cytochrome P450 2D6 as major enzyme involved in the O-demethylation of the designer drug p-methoxymethamphetamine. 61
15039289 2004
50
Stable expression of human cytochrome P450 2D6*10 in HepG2 cells. 61
14716830 2004

Variations for Cytochrome P450 2d6 Variant

Expression for Cytochrome P450 2d6 Variant

Search GEO for disease gene expression data for Cytochrome P450 2d6 Variant.

Pathways for Cytochrome P450 2d6 Variant

GO Terms for Cytochrome P450 2d6 Variant

Sources for Cytochrome P450 2d6 Variant

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....